Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers. The company's lead program, AlloNK, is an off-the-shelf NK cell therapy designed to treat multiple autoimmune conditions including rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, pemphigus vulgaris, and anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes. AlloNK is also being evaluated for B-cell non-Hodgkin lymphoma treatment.

Beyond its lead candidate, Artiva is advancing a pipeline of chimeric antigen receptor (CAR)-NK cell products. AB-201 is an allogeneic anti-HER2 targeting CAR-NK cell therapy in development for solid tumors including breast, gastric, esophageal, and bladder cancers. AB-205, an allogeneic anti-CD5 CAR-NK candidate, targets hematological malignancies. The company's therapeutic approach focuses on leveraging NK cells as an off-the-shelf, allogeneic platform.

Based in San Diego, California, Artiva was incorporated in 2019 and operates with approximately 106 full-time employees. The company is publicly traded on Nasdaq and is currently in clinical development stages, with no approved commercial products generating revenue.